Boston Scientific to acquire medical device specialists focused on stroke prevention for $1.2B

Michael Walter | June 19, 2024 | Cardiovascular Business | Economics

Boston Scientific has agreed to acquire Silk Road Medical, a California-based medical device company focused on designing new stroke treatments, for approximately $1.16 billion. The final purchase price broke down to $27.50 per share, a 38% premium compared to Silk Road Medical’s volume-weighted average stock price over the last two months.

Silk Road Medical is known for developing transcarotid artery revascularization (TCAR), a new minimally invasive procedure intended to reduce the risk of stroke in patients with carotid artery disease. During TCAR, an interventional cardiologist accesses the patient’s carotid artery through a small incision in their neck and then temporarily reverses blood flow away from the brain. A stent is then implanted into the patient to provide long-term stabilization and reduce the long-term risk of stroke.

The Silk Road Medical TCAR system gained U.S. Food and Drug Administration approval in 2015 based on data from multiple clinical trials. The TCAR system and related devices represent the only technology on the market currently being used to guide and perform TCAR procedures.

“The TCAR platform developed by Silk Road Medical is a notable advancement in the field of vascular medicine, which has revolutionized stroke prevention and the treatment of carotid artery disease,” Cat Jennings, Boston Scientific’s president of vascular and peripheral interventions, said in a prepared statement. “We believe the addition of this clinically differentiated technology to our vascular portfolio demonstrates our continued commitment to provide meaningful innovation for physicians who care for patients with peripheral vascular disease.”

Boston Scientific and Silk Road Medical expect to finalize this acquisition by the end of 2024. At that point, Silk Road Medical will be a whole-owned subsidiary of Boston Scientific.

Private equity in healthcare: Cardiologists, government officials and advocacy groups share their perspective

It’s official: Johnson & Johnson completes $13B Shockwave Medical acquisition

Private equity-backed cardiology group acquires Arizona practice with 4 locations

How a big CMS update on carotid stenting could impact interventional cardiology

FDA approves Boston Scientific’s new drug-coated balloon for coronary in-stent restenosis

Boston Scientific to acquire majority stake of interventional device company for $523M

Boston Scientific finalizes acquisition of Baylis Medical with $1.75B payment

Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Health Exec

Tom Price: Medical residency slots need to expand to combat physician shortages

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.

Health Imaging

Tariffs will have a significant impact on the nuclear imaging supply chain in the US

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

Radiology Business

U.S. iodine contrast supply may not be subject to proposed 25% tariffs

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.